Check out our comprehensive educational activities here

Venetoclax in Combination with Gilteritinib in Patients with Relapsed/Refractory AML

Dr. Daver covers the results of the phase 1b study of venetoclax in combination with gilteritinib in patients with relapsed/refractory AML and what this approval could mean for future treatment.

Published on March 23, 2020 in Treatment

Challenges Associated with Relapse after Transplant in AML

Relapse is a devastating complication for patients with AML after transplant. In this activity, Dr. Giralt explains next steps.

Published on March 18, 2020 in Treatment

The Challenge of p53 Mutations in Treating AML

In this activity, Dr. Stein reviews the combination of APR-246 and azacitidine.

Published on March 16, 2020 in Treatment

COVID-19 Resources

MediCom Worldwide is committed to providing the most timely and relevant education to our membership, with the goal of improving patient care. In light of the COVID-19 pandemic, we are providing you with links to available resources on both general information about COVID-19 and the impact on patient care in the hematology/oncology setting. Please check these links periodically for any updates.

Published on March 16, 2020 in Treatment

Updates on the SIERRA Trial: An Investigation of Apamistamab-I-131

The SIERRA trial is a randomized phase 3 trial of an investigational radio-immune conjugate. In this activity, Dr. Giralt provides an update on the trial and what he hopes for in the future.

Published on March 9, 2020 in Treatment

Q-TWIST Analysis of Quizartinib vs. Salvage Chemotherapy in Patients with R/R FLT3-ITD AML

There has been much interest in developing new strategies for patients with FLT3-ITD mutated disease. In this activity, Dr. Cortes discusses the role of quizartinib in this setting.

Published on March 6, 2020 in Treatment

Emerging Treatment Options and Maintenance Therapy Following a Stem Cell Transplantation in Patients with AML

In this activity, Dr. Giralt discusses the emerging treatment options and maintenance therapy following a stem cell transplantation in patients with AML.

Published on February 26, 2020 in Treatment

Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice

The treatment of acute myeloid leukemia (AML) has advanced significantly over the past few years due to an improved understanding of the roles of molecular stratification, clonal heterogeneity, and clonal evolution in therapy and prognostication for patients with the disease. While clinicians have traditionally used factors such as age and performance status (PS) to guide therapy, new and very predictive molecular and chromosomal factors now provide critical information about patient prognosis and can also predict therapy pathways and guide intensity of therapy to improve patient management and overall outcomes.

For more information on developing optimal treatment strategies for your patients with AML, please view the CE Education activity here.

Published on February 17, 2020 in Treatment

Optimizing Outcomes in Relapsed/Refractory AML: Incorporating New Treatments into Practice

The treatment of acute myeloid leukemia (AML) has advanced significantly over the past few years due to an improved understanding of molecular annotation, clonal heterogeneity, and prognostication for patients with leukemia. While clinicians have traditionally used factors such as age and performance status (PS) to guide therapy, newly recognized predictive molecular and chromosomal factors now provide critical information about patient prognosis and can also predict therapy pathways and guide intensity of therapy to improve patient management and overall outcomes.

For more information on developing optimal treatment strategies for your patients with AML, please view the CE Education activity here.

Published on January 27, 2020 in Treatment

Updates on the Most Anticipated Data Presented at ASH 2019

In this clip, Dr. Daver discusses a few exciting studies presented at ASH 2019, including two agents that are especially active.

Published on December 23, 2019 in Treatment